Title: A Phase III, Randomized, Double Blind, Placebo-Controlled Trial Of Acyclovir For The Reduction Of HIV Acquisition Among High-Risk HSV-2 Sero-positive, HIV Sero-negative Individuals (HPTN 039)

Sponsor: Division of AIDS, US National Institute of Allergy and Infectious Diseases

Principal Investigator: Dr Frances Cowan
This email address is being protected from spam bots, you need Javascript enabled to view it

Study Summary

The purpose of the study is to determine the efficacy of twice daily acyclovir in preventing HIV infection among high risk HIV negative, HSV-2 sero-positive women and men who have sex with men (WSM, MSM). This is a multi-site study that is being conducted in three African sites namely Zimbabwe, Zambia and South Africa, 3 USA Sites and 1 site in Peru, South America. The study is closed to accrual, having enrolled a total of 3277 participants across all sites.

In Zimbabwe, the study is known as the CHANZI study, (Combating HIV and AIDS iN ZImbabwe). It is being carried out at the Zengeza 3 CRS. CHANZI started recruiting in July 2004 and ended in April 2006, bringing the total enrolment at this site to 370. Each participant was randomized to either acyclovir or matching placebo tablets and will be followed up for 12 or 18 months depending on when they enrolled.

The last participant is expected to exit in October 2007.

Study contacts

Euphemia Sibanda (Pharmacist/Study Coordinator)
This email address is being protected from spam bots, you need Javascript enabled to view it

Grecenia Ndhovu (Clinic Manager)
This email address is being protected from spam bots, you need Javascript enabled to view it

View our Publications
View our CRS photo gallery